BR112015023705A2 - composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) - Google Patents
composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)Info
- Publication number
- BR112015023705A2 BR112015023705A2 BR112015023705A BR112015023705A BR112015023705A2 BR 112015023705 A2 BR112015023705 A2 BR 112015023705A2 BR 112015023705 A BR112015023705 A BR 112015023705A BR 112015023705 A BR112015023705 A BR 112015023705A BR 112015023705 A2 BR112015023705 A2 BR 112015023705A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- formula
- solvate
- hydrate
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
resumo composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) a presente revelação refere-se, inter alia, a composições e métodos para tratar doenças virais e câncer. são revelados diésteres fosfonato de nucleosídeo acíclico anticâncer e antiviral lipofílicos, preparação dos mesmos e métodos de uso dos compostos para tratar doenças virais e câncer. 1/1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361793993P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/027005 WO2014143643A1 (en) | 2013-03-15 | 2014-03-14 | Acyclic nucleoside phosphonate diesters |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015023705A2 true BR112015023705A2 (pt) | 2017-07-18 |
BR112015023705A8 BR112015023705A8 (pt) | 2020-03-17 |
Family
ID=51493342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015023705A BR112015023705A8 (pt) | 2013-03-15 | 2014-03-14 | compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia) |
Country Status (25)
Country | Link |
---|---|
US (11) | US8835630B1 (pt) |
EP (2) | EP3401320B1 (pt) |
JP (2) | JP6462659B2 (pt) |
KR (1) | KR20150130355A (pt) |
CN (3) | CN107056838A (pt) |
AU (2) | AU2014228321C1 (pt) |
BR (1) | BR112015023705A8 (pt) |
CA (1) | CA2906680A1 (pt) |
CY (1) | CY1120839T1 (pt) |
DK (1) | DK2970346T3 (pt) |
EA (2) | EA032227B1 (pt) |
ES (1) | ES2687958T3 (pt) |
HK (1) | HK1219279A1 (pt) |
HR (1) | HRP20181871T1 (pt) |
HU (1) | HUE041346T2 (pt) |
IL (1) | IL241554B (pt) |
LT (1) | LT2970346T (pt) |
MX (1) | MX367403B (pt) |
PL (1) | PL2970346T3 (pt) |
PT (1) | PT2970346T (pt) |
RS (1) | RS57796B1 (pt) |
SG (2) | SG10201800188SA (pt) |
SI (1) | SI2970346T1 (pt) |
TW (1) | TWI642677B (pt) |
WO (1) | WO2014143643A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
CN107056838A (zh) | 2013-03-15 | 2017-08-18 | 加利福尼亚大学董事会 | 无环核苷膦酸二酯 |
HRP20220651T1 (hr) | 2014-09-15 | 2022-08-19 | The Regents Of The University Of California | Nukleotidni analozi |
EP3875462A1 (en) | 2015-09-15 | 2021-09-08 | The Regents of The University of California | Nucleotide analogs |
CN108137630A (zh) * | 2016-09-23 | 2018-06-08 | 鲁汶天主教大学 | 氟化无环核苷膦酸酯的前药 |
AU2017378959B2 (en) * | 2016-12-23 | 2021-09-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nucleoside phosphate compound and preparation method and use thereof |
CN108276444A (zh) * | 2017-01-06 | 2018-07-13 | 米文君 | 一类新的化合物及其用途 |
CN107011383A (zh) * | 2017-04-28 | 2017-08-04 | 朱孝云 | 氘代无环核苷膦酸二酯 |
CN111051326A (zh) * | 2017-10-23 | 2020-04-21 | 四川科伦博泰生物医药股份有限公司 | 核苷磷酸类化合物及其制备方法和用途 |
WO2019237957A1 (zh) | 2018-06-12 | 2019-12-19 | 四川科伦博泰生物医药股份有限公司 | 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途 |
AU2020334152A1 (en) * | 2019-08-22 | 2022-03-24 | Emory University | Nucleoside prodrugs and uses related thereto |
WO2022020793A1 (en) * | 2020-07-24 | 2022-01-27 | The Regents Of The University Of California | Antiviral prodrugs, pharmaceutical formulations, and methods |
AU2021330835B2 (en) | 2020-08-24 | 2023-12-14 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
WO2022271880A1 (en) * | 2021-06-22 | 2022-12-29 | Rome Therapeutics, Inc. | Methods of treating medical conditions and inhibiting line1 reverse transcriptase using a substituted adeninyl-propyloxy phosphonic acid or related compound |
WO2023183852A1 (en) * | 2022-03-23 | 2023-09-28 | Board Of Regents Of The University Of Nebraska | Phosphonate prodrugs and use thereof |
EP4337667A1 (en) | 2022-07-21 | 2024-03-20 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
CS233665B1 (en) | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
CS263952B1 (en) | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
CS263951B1 (en) | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
CS263956B1 (cs) | 1986-07-18 | 1989-05-12 | Holy Antonin | Způsob výroby 9- (S) -, (3-hydroxy-2-fosfonylmetboxypropyl) adeninu |
CS263955B1 (cs) | 1986-07-18 | 1989-05-12 | Holy Antonin | Způsob výroby N-(3-hydroxy-2-fosfonylmethoxypropyl)derivátů heterocyklických bází |
CS264222B1 (en) | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
CS263953B1 (cs) | 1986-07-18 | 1989-05-12 | Holy Antonin | Způsob výroby 9-(S)- nebo 9-(RS)-(3 hydroxy-2-íosfonylmethoxypropyl)- ads-ninu |
DE3778626D1 (de) | 1986-09-27 | 1992-06-04 | Toyo Jozo Kk | Nukleosid-phospholipid-konjugat. |
US5650510A (en) | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US6599887B2 (en) | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5033352A (en) | 1989-01-19 | 1991-07-23 | Yamaha Corporation | Electronic musical instrument with frequency modulation |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5688778A (en) | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
CZ285420B6 (cs) | 1990-04-24 | 1999-08-11 | Ústav Organické Chemie A Biochemie Avčr | N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
AU660417B2 (en) | 1990-06-15 | 1995-06-29 | University Of North Carolina At Chapel Hill, The | Ether lipid-nucleoside covalent conjugates |
DE4026265A1 (de) | 1990-08-20 | 1992-02-27 | Boehringer Mannheim Gmbh | Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel |
DE69129650T2 (de) * | 1990-09-14 | 1999-03-25 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
PL169576B1 (pl) | 1990-10-12 | 1996-08-30 | Max Planck Gesellschaft | Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL |
DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
GB9205917D0 (en) | 1992-03-18 | 1992-04-29 | Smithkline Beecham Plc | Pharmaceuticals |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5532225A (en) | 1992-07-31 | 1996-07-02 | Sri International | Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods |
US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
US6444656B1 (en) | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
US6005107A (en) | 1992-12-23 | 1999-12-21 | Biochem Pharma, Inc. | Antiviral compounds |
GB9226879D0 (en) | 1992-12-23 | 1993-02-17 | Iaf Biochem Int | Anti-viral compounds |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5817647A (en) | 1993-04-01 | 1998-10-06 | Merrell Pharmaceuticals Inc. | Unsaturated acetylene phosphonate derivatives of purines |
EP0632048B1 (en) | 1993-06-29 | 2001-03-21 | Mitsubishi Chemical Corporation | Phosphonate-nucleotide ester derivatives |
US5656745A (en) | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
JPH09506333A (ja) | 1993-09-17 | 1997-06-24 | ギリアード サイエンシーズ,インコーポレイテッド | 治療化合物の投薬方法 |
DE4418690A1 (de) | 1994-05-28 | 1996-01-11 | Boehringer Mannheim Gmbh | Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel |
EP0690058B1 (de) | 1994-06-29 | 1999-09-08 | Ciba SC Holding AG | Neue Kristallmodifikation eines Diketopyrrolopyrrolpigments |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
US7517858B1 (en) | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
US6197775B1 (en) | 1995-06-15 | 2001-03-06 | Mitsubishi Chemical Corporation | Phosphonate nucleotide derivatives |
US5717095A (en) | 1995-12-29 | 1998-02-10 | Gilead Sciences, Inc. | Nucleotide analogs |
TW369536B (en) | 1996-01-18 | 1999-09-11 | Mitsubishi Chem Corp | Phosphonate nucleotide compounds |
US5877166A (en) | 1996-04-29 | 1999-03-02 | Sri International | Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents |
US6686462B2 (en) | 1997-02-28 | 2004-02-03 | The Regents Of The University Of California | Antiviral compounds and methods of administration |
AU6473098A (en) | 1997-03-24 | 1998-10-20 | Eli Lilly And Company | Difluoronucleoside phosphonic acids and derivatives thereof |
KR20010024743A (ko) | 1997-12-17 | 2001-03-26 | 몽고메리 죤 에이 | 뉴라미니다아제 감염저해 물질로서 유용한 치환된시클로펜탄 및 시클로펜틴 화합물 |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6455571B1 (en) | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
AU4125099A (en) | 1998-06-01 | 1999-12-20 | S & T Science And Technology Inc. | Antiviral phosphorus derivatives of 4'-thio-5-ethyl-2'-deoxyuridine |
AU2645199A (en) | 1998-11-18 | 2000-06-05 | Viktor Veniaminovich Tets | Dialkyl-1-aryl-1-(2,4-dioxo-5-amino-1,3-pyrimidin-5-yl)methy lphosphonates |
US7026469B2 (en) | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
JP4993649B2 (ja) | 1999-12-03 | 2012-08-08 | ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア サン ディエゴ | ホスホネート化合物 |
US6767900B2 (en) | 2000-02-29 | 2004-07-27 | Mitsubishi Pharma Corporation | Phosphonate nucleotide compound |
MY141789A (en) | 2001-01-19 | 2010-06-30 | Lg Chem Investment Ltd | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same. |
CZ292199B6 (cs) | 2001-03-08 | 2003-08-13 | Ústav organické chemie a biochemie AV ČR | O-Fosfonomethylcholin a jeho alkylestery, způsob jejich přípravy a použití |
RU2187509C1 (ru) | 2001-03-26 | 2002-08-20 | Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" | Производные 5'-h-фосфоната 3'-азидо-3'-дезокситимидина и фармацевтические композиции на их основе |
KR20020097384A (ko) | 2001-06-20 | 2002-12-31 | 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 | 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제 |
AU2002315625B2 (en) | 2001-06-29 | 2008-05-01 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | 6-2'-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity |
US20040023928A1 (en) | 2001-10-31 | 2004-02-05 | Colacino Joseph Matthew | Phosphonate nucleotide and thiadiazole compounds for the treatment of smallpox |
US7388002B2 (en) * | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
CN1617877A (zh) | 2001-12-07 | 2005-05-18 | 三菱制药株式会社 | 膦酸酯核苷酸类似物在治疗乙肝病毒感染方面的用途 |
CA2481285A1 (en) | 2002-04-26 | 2003-11-06 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
WO2003099294A1 (fr) | 2002-05-24 | 2003-12-04 | Mitsubishi Pharma Corporation | Medicaments a selectivite tissulaire amelioree |
WO2004096286A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
EP1617848A2 (en) | 2003-04-25 | 2006-01-25 | Gilead Sciences, Inc. | Anti-cancer phosphonate conjugates |
CN1805966B (zh) | 2003-06-16 | 2013-03-13 | 捷克科学院有机化学和生物化学研究所 | 作为抗病毒核苷酸类似物的含膦酸酯基团的嘧啶化合物 |
BRPI0418251C1 (pt) | 2003-12-30 | 2021-05-25 | Gilead Sciences Inc | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo |
WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
WO2005087788A2 (en) | 2004-03-04 | 2005-09-22 | The Regents Of The University Of California | Methods for preparation of nucleoside phosphonate esters |
WO2006076015A2 (en) | 2004-04-30 | 2006-07-20 | The Regents Of The University Of California | 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof |
ES2401285T3 (es) * | 2004-12-16 | 2013-04-18 | The Regents Of The University Of California | Fármacos con el pulmón como diana |
CN1827627B (zh) * | 2005-03-04 | 2011-05-11 | 北京美倍他药物研究有限公司 | 新的无环核苷膦酸及其酯衍生物及其医药用途 |
EP1865967A4 (en) * | 2005-04-08 | 2011-02-09 | Chimerix Inc | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES |
EP1879657A2 (en) | 2005-04-25 | 2008-01-23 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of compounds to enhance processivity of telomerase |
WO2007002808A1 (en) | 2005-06-29 | 2007-01-04 | Gilead Sciences, Inc. | Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof |
ES2600792T3 (es) * | 2006-05-03 | 2017-02-10 | Chimerix, Inc. | Alcoxialquilésteres metabólicamente estables de fosfonatos, fosfonatos nucleosídicos y fosfatos nucleosídicos antivirales o antiproliferativos |
CN101089004A (zh) * | 2006-06-13 | 2007-12-19 | 上海舒盟化学科技有限公司 | 一种新型的膦酸酯-核苷酸化合物 |
RU2474427C2 (ru) * | 2006-12-20 | 2013-02-10 | Универзитетсклиникум Хамбург-Эппендорф | Применение тризамещенных соединений глицерина для лечения гематологических злокачественных опухолей |
WO2008104408A2 (en) | 2007-02-27 | 2008-09-04 | K. U. Leuven Research & Development | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents |
EP2155257B1 (en) | 2007-04-27 | 2016-10-05 | Chimerix, Inc. | Methods of reducing nephrotoxicity in subjects administered with nucleoside |
US8993542B2 (en) | 2008-01-25 | 2015-03-31 | Chimerix Inc. | Methods of treating viral infections |
TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
CN101307076A (zh) * | 2008-05-30 | 2008-11-19 | 秦引林 | 一种具有肝靶向抗乙肝病毒作用的前药 |
WO2010091386A2 (en) | 2009-02-06 | 2010-08-12 | Rfs Pharma, Llc | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections |
DE102009020261A1 (de) | 2009-05-07 | 2010-11-11 | Universität Hamburg | Verfahren zur festphasengestützten Herstellung phosphatverbrückter Nucleosid-Konjugate |
TW201107342A (en) | 2009-05-20 | 2011-03-01 | Chimerix Inc | Compounds, compositions and methods for treating viral infection |
US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
WO2011011710A1 (en) | 2009-07-24 | 2011-01-27 | Chimerix, Inc. | Methods of treating viral infections |
AU2010279678B2 (en) * | 2009-08-03 | 2015-09-10 | Emergent Biodefense Operations Lansing Llc | Composition and methods of treating viral infections and viral induced tumors |
US20130072458A1 (en) | 2009-10-30 | 2013-03-21 | Chimerix, Inc. | Methods of Treating Viral Associated Diseases |
EP2534150B1 (en) | 2010-02-12 | 2017-04-05 | Chimerix, Inc. | Methods of treating viral infection |
US20110218241A1 (en) | 2010-03-06 | 2011-09-08 | Cacao Bio-Technologies, Llc | Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts |
CN102939291B (zh) * | 2010-04-14 | 2016-09-07 | 加利福尼亚大学董事会 | 用于病毒感染治疗的具有降低的毒性的膦酸酯 |
ES2604137T3 (es) | 2010-08-31 | 2017-03-03 | Chimerix, Inc. | Derivados de éster de fosfonato y métodos de síntesis de los mismos |
CN107056838A (zh) | 2013-03-15 | 2017-08-18 | 加利福尼亚大学董事会 | 无环核苷膦酸二酯 |
CA2929593C (en) | 2013-11-15 | 2020-03-10 | Chimerix Inc. | Morphic forms of hexadecyloxypropyl-phosphonate esters |
HRP20220651T1 (hr) | 2014-09-15 | 2022-08-19 | The Regents Of The University Of California | Nukleotidni analozi |
EP3875462A1 (en) | 2015-09-15 | 2021-09-08 | The Regents of The University of California | Nucleotide analogs |
-
2014
- 2014-03-14 CN CN201710272746.1A patent/CN107056838A/zh active Pending
- 2014-03-14 SG SG10201800188SA patent/SG10201800188SA/en unknown
- 2014-03-14 KR KR1020157027425A patent/KR20150130355A/ko not_active Application Discontinuation
- 2014-03-14 PL PL14764430T patent/PL2970346T3/pl unknown
- 2014-03-14 CA CA2906680A patent/CA2906680A1/en not_active Abandoned
- 2014-03-14 EA EA201591757A patent/EA032227B1/ru unknown
- 2014-03-14 US US14/211,235 patent/US8835630B1/en active Active
- 2014-03-14 RS RS20181142A patent/RS57796B1/sr unknown
- 2014-03-14 SG SG11201507101XA patent/SG11201507101XA/en unknown
- 2014-03-14 AU AU2014228321A patent/AU2014228321C1/en not_active Ceased
- 2014-03-14 EA EA201892769A patent/EA201892769A3/ru unknown
- 2014-03-14 CN CN201810387212.8A patent/CN108619161A/zh active Pending
- 2014-03-14 SI SI201430875T patent/SI2970346T1/sl unknown
- 2014-03-14 CN CN201480026709.7A patent/CN105246902B/zh not_active Expired - Fee Related
- 2014-03-14 BR BR112015023705A patent/BR112015023705A8/pt not_active Application Discontinuation
- 2014-03-14 MX MX2015012633A patent/MX367403B/es active IP Right Grant
- 2014-03-14 WO PCT/US2014/027005 patent/WO2014143643A1/en active Application Filing
- 2014-03-14 EP EP18179904.0A patent/EP3401320B1/en active Active
- 2014-03-14 JP JP2016502307A patent/JP6462659B2/ja active Active
- 2014-03-14 PT PT14764430T patent/PT2970346T/pt unknown
- 2014-03-14 EP EP14764430.6A patent/EP2970346B1/en active Active
- 2014-03-14 US US14/211,002 patent/US9629860B2/en active Active
- 2014-03-14 HU HUE14764430A patent/HUE041346T2/hu unknown
- 2014-03-14 ES ES14764430.6T patent/ES2687958T3/es active Active
- 2014-03-14 TW TW103109799A patent/TWI642677B/zh not_active IP Right Cessation
- 2014-03-14 LT LTEP14764430.6T patent/LT2970346T/lt unknown
- 2014-03-14 DK DK14764430.6T patent/DK2970346T3/en active
- 2014-08-20 US US14/463,908 patent/US9156867B2/en active Active
-
2015
- 2015-09-10 IL IL241554A patent/IL241554B/en active IP Right Grant
- 2015-10-02 US US14/874,027 patent/US9387217B2/en active Active
-
2016
- 2016-06-10 US US15/179,209 patent/US9775852B2/en active Active
- 2016-06-24 HK HK16107381.4A patent/HK1219279A1/zh not_active IP Right Cessation
-
2017
- 2017-03-20 US US15/463,962 patent/US20170189430A1/en not_active Abandoned
- 2017-06-08 US US15/617,841 patent/US10076532B2/en active Active
- 2017-11-10 US US15/809,400 patent/US10076533B2/en active Active
- 2017-11-14 US US15/812,814 patent/US10195222B2/en active Active
-
2018
- 2018-08-24 US US16/111,378 patent/US10449207B2/en active Active
- 2018-10-30 CY CY181101116T patent/CY1120839T1/el unknown
- 2018-11-08 HR HRP20181871TT patent/HRP20181871T1/hr unknown
- 2018-12-26 JP JP2018242188A patent/JP2019069984A/ja active Pending
-
2019
- 2019-03-22 AU AU2019201990A patent/AU2019201990B2/en not_active Ceased
- 2019-09-11 US US16/567,092 patent/US20190388442A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
CY1119227T1 (el) | Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock | |
MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
EA201591301A1 (ru) | Новые пиримидиновые и пиридиновые соединения и их применение | |
BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
MY171577A (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
BR112012023660B8 (pt) | usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer | |
CY1120378T1 (el) | Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης) | |
PH12014501283A1 (en) | 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication | |
EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
MX2013012588A (es) | Inhibidores de cinasa. | |
EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
EA201600337A1 (ru) | 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний | |
EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
UY32055A (es) | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. | |
BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |